The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats

International Journal of Molecular Medicine

Volumn 26, Issue 4, 2010, Pages 541-547

  Gao, Yu Fei ^a   Zhu, Xiao Duo ^b   Shi, Dong Mei ^c   Jing, Zhi Cheng ^d   Li, Li ^a   Ma, Dan ^a   Fan, Zhi Xin ^a   Li, Jian ^e   Wang, Yi Wei ^a   Wu, Bing Xiang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Province Hospital   (China)

^c Second Heilongjiang Province Hospital   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Longnan Hospital   (China)

Author keywords

Atorvastatin; Jab1; p27; p38; Pulmonary arterial hypertension

Indexed keywords

ATORVASTATIN; PROTEIN JAB1; PROTEIN P27; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG RESECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; RIGHT VENTRICLE HYPERTROPHY INDEX; SCORING SYSTEM; WESTERN BLOTTING;

ANIMALS; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PNEUMONECTOMY; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEINS; PULMONARY ARTERY; PYRROLES; RATS; RATS, WISTAR;

EID: 77957877167     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000497     Document Type: Article

References (28)

1. Galie N, Torbicki A, Barst R, et al: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 25: 2243-2278, 2004.
2. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ and Yuan JX: Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 68: 75-103, 2004. (Pubitemid 39093882)
3. Hoeper MM: Drug treatment of pulmonary arterial hypertension. Current and future agents. Drugs 65: 1337-1354, 2005.
4. Humbert M, Sitbon O and Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
5. Sitbon O, Humbert M, Nunes H, et al: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780-788, 2002.
6. Yuan JX and Rubin LJ: Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111: 534-538, 2005.
7. Laufs U, Fata VL and Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272: 31725-31729, 1997. (Pubitemid 28013321)
8. Takemoto M and Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
9. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719, 1998.
10. Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
11. Muller C, Kiehl MG, van de Loo J and Koch OM: Lovastatin induces p21WAF1/ Cip1 in human vascular smooth muscle cells: influences on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med 3: 63-68, 1999.
12. Gurbanov E and Shiliang X: The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg 30: 499-507, 2006.
13. Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK and Weber PC: HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 169: 251-258, 2003. (Pubitemid 37297471)
14. Newton CJ, Xie YX, Burgoyne CH, et al: Fluvastatin induces apoptosis of vascular endothelial cells: blockade by glucocorticoids. Cardiovasc Surg 11: 52-60, 2003.
15. Sato I, Ma L, Ikeda M, Morita I and Murota S: Simvastatin, a potent HMG-COA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro. J Atheroscler Thromb 4: 102-106, 1998.
16. Indolfi C, Cioppa A, Stabile E, et al: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35: 214-221, 2000.
17. Almuti K, Rimawai R, Dpevack D and Ostfeld RJ: Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109: 7-15, 2006.
18. Nishimura T, Faul JL, Berry GJ, et al: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166: 1403-1408, 2002. (Pubitemid 35292709)
19. Nishimura T, Vaszar LT, Faul JL, et al: Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645, 2003.
20. Kohno M, Shinomiya K, Abe S, et al: Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-COA reductase inhibitor pitavastatin. Hypertens Res 25: 279-285, 2002.
21. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
22. Laufs U, Marra D, Node K and Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem 274: 21926-21931, 1999. (Pubitemid 129519746)
23. Kyriakis JM and Avruch J: Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313-24316, 1996.
24. Miura S, Matsuo Y, Kawamura A, Saku K: JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27 (kip1) and Ras/p21 (waf1) pathways. Atherosclerosis 182: 267-275, 2005.
25. Lu J, Shimpo H, Shimamoto A, et al: Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thor Cardiovasc Surg 128: 850-859, 2004.
26. Yu L, Quinn DA, Garg HG and Hales CA: Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 345: 1565-1572, 2006. (Pubitemid 43817908)
27. Sui L, Dong Y, Ohno M, et al: Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7: 4130-4135, 2001.
28. Tomoda K, Kubota Y, Arata Y, et al: The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 277: 2302-2310, 2002.